Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

1. García Trevijano Cabetas, M.
2. Escario-Gómez, M.
3. González-Del Valle, L.
4. Sobrino Jiménez, C.
5. Bilbao Gomez-Martino, C.
6. Romero-Garrido, J.A.
7. Benedi-González, J.
8. Espinosa Arranz, E.
9. Díaz Almirón, M.
10. Herrero Ambrosio, A.